Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Haematological malignancies

627MO - Orelabrutinib plus RCHOP for previously untreated non-germinal center b cell-like (GCB) diffuse large b cell lymphoma (DLBCL) patients with extranodal disease


12 Sep 2022


Mini Oral session: Haematological malignancies


Tumour Site



Mingyue Wang


Annals of Oncology (2022) 33 (suppl_7): S283-S294. 10.1016/annonc/annonc1055


M. Wang, Q. Ke, Z. Li, D. Zhou, C. Liao, J. Sun, B. Guo, H. Cen

Author affiliations

  • Oncology, Guangxi Medical University Affiliated Tumor Hospital and Oncology Medical Center, 530021 - Nanning/CN


This content is available to ESMO members and event participants.

Abstract 627MO


The prognosis of patients with non-GCB DLBCL is poor, especially in those with extranodal invasion which has strong invasiveness and rapid clinical progress. How to improve the prognosis of these patients is the main challenge of DLBCL therapy. Bruton tyrosine kinase (BTK) is a member of the non-receptor tyrosine kinase Tec family; it is involved in the proliferation, adhesion and metastasis of B cells. BTK inhibitor showed activity in relapsed/refractory non-GCB DLBCL. Orelabrutinib is a new oral covalent BTK inhibitor; this study aimed to analyze the efficacy and safety of orelabrutinib plus RCHOP for previously untreated non-GCB DLBCL patients with extranodal disease.


Patients with IHC-confirmed non-GCB DLBCL and PET-CT confirmed extranodal invasion were enrolled in this study. Patients received standard RCHOP with orelabrutinib(150 mg/d, po) on a 21-day cycle for 6 cycles.Primary end point was response rate, secondary end points included progression-free survival (PFS), overall survival (OS), and safety.


22 patients were enrolled, with a median age of 52 years (21-72), including 10 males,11 cases with IPI equal to or greater than 3 points,12 cases with double expressor (DE) DLBCL, and 19 cases with stage IV disease. The overall response rate was 90.9%( 20/22), complete response (CR) rate was 77.3% (17/22). The CR rate was 75% (9/12) in patients with DE DLBCL and 80% (8/10) in those with non-DE DLBCL.The median follow up was 11 months,3 patients with DE DLBCL had progressive disease, all patients survived. Serious AEs included febrile neutropenia (3 cases) and atrial flutter (1 case).


The efficacy of orelabrutinib plus RCHOP for non-GCB DLBCL with extranodal disease is impressive in this single center clinical practice and the toxicity is acceptable.

Clinical trial identification

Legal entity responsible for the study

The authors.


Natural Science Foundation of Guangxi Province, Grant/Award Number: 2018GXNSFBA281026.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.